{"id":"dyphylline","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DYPHYLLINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:52:58.970743+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T04:53:13.547064+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:53:06.718587+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DYPHYLLINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:53:07.494085+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Phosphodiesterase 3A inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:53:08.088429+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1752/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:53:07.972487+00:00"}},"_dailymed":null,"aiSummary":"Diphylline is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.","_scrapedAt":"2026-03-28T00:37:32.959Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:53:13.548171+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT00345930","phase":"","title":"DILIN - Prospective Study","status":"RECRUITING","sponsor":"Duke University","startDate":"2004-09","conditions":"Liver Diseases","enrollment":4000},{"nctId":"NCT04810819","phase":"NA","title":"Clinical Study of the Effect of Methylprednisolone Combined","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2021-07-01","conditions":"Methylprednisolone;Dihydroxypropyltheophylline;One Lung Ventilation;Respiratory Dynamics","enrollment":110}],"_emaApprovals":[],"_faersSignals":[{"count":10,"reaction":"DYSPNOEA"},{"count":9,"reaction":"ANXIETY"},{"count":9,"reaction":"CHEST PAIN"},{"count":9,"reaction":"OVERDOSE"},{"count":9,"reaction":"PAIN"},{"count":9,"reaction":"PNEUMONIA"},{"count":8,"reaction":"DIZZINESS"},{"count":8,"reaction":"DRUG INEFFECTIVE"},{"count":8,"reaction":"NAUSEA"},{"count":7,"reaction":"HYPERSENSITIVITY"}],"crossReferences":{"chemblId":"CHEMBL1752"},"_approvalHistory":[],"publicationCount":81,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"DYPHYLLINE","genericName":"DYPHYLLINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1951","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:53:13.548171+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}